Subtype
Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm
CI-CAN-00001188Explore in graph →
7 active trials
- NCIt
- C6311
Loading cancer entity…
Subtype
CI-CAN-00001188Explore in graph →
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment |
| active not recruiting |
| Phase 2 |
| 24 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Oct 14, 2025 |
| clinicaltrials |
Data updated 22 days agoSource updated Sep 9, 2026source: clinicaltrials